ABSTRACT
Background The prospective Kiel Inflammatory Bowel Disease (IBD) Family Cohort Study (KINDRED cohort) was initiated in 2013 to systematically and extensively collect data and biosamples from index IBD patients and their relatives (e.g., blood, stool), a population at high risk for IBD development. Regular follow-ups were conducted to collect updated health and lifestyle information, to obtain new biosamples, and to capture the incidence of IBD during development. By combining taxonomic and imputed functional microbial data collected at successive time points with extensive anthropometric, medical, nutritional, and social information, this study aimed to characterize the factors influencing the microbiota in health and disease via detailed ecological analyses.
Results Using two dysbiosis metrics (MD-index, GMHI) trained on the German KINDRED cohort, we identified strong and generalizable gradients within and across different IBD cohorts, which correspond strongly with IBD pathologies, physiological manifestations of inflammation (e.g., Bristol stool score, ASCA IgA/IgG), genetic risk for IBD, and general risk of disease onset. Anthropometric and medical factors influencing transit time strongly modify bacterial communities. Various Enterobacteriaceae (e.g., Klebsiella sp.) and opportunistic Clostridia pathogens (e.g., C. XIVa clostridioforme), characterize in combination with ectopic oral taxa (e.g. Veillonella sp., Cand. Saccharibacteria sp., Fusobacterium nucleatum) the distinct and chaotic IBD-specific communities. Functionally, amino acid metabolism and flagellar assembly are beneficial, while mucolytic functions are associated with IBD.
Conclusions Our findings demonstrate broad-scale ecological patterns which indicate drastic state transitions of communities into characteristically chaotic communities in IBD patients. These patterns appear to be universal across cohorts and influence physiological signs of inflammation, display high resilience, but show only little heritability/intrafamily transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The KINDRED cohort received funding from the German Research Foundation (DFG) through Excellence Clusters "Inflammation at interfaces" (EXC 306) and "Precision Medicine in Inflammation" (PMI; EXC 2167), as well as from the Research Unit miTarget (FOR 5042). This study was also supported by a grant from the German Ministry of Education and Research (01ZX1606A).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was performed in accordance with the principles of the Declaration of Helsinki. Approval was granted by the ethics committee of the Medical Faculty of Kiel University (AZ A117/13). Ethical approval for the Maltese cohorts was obtained from the University of Malta Research Ethics Committee (Ref 32/2017) and patients were recruited from the gastroenterology outpatient clinic at Mater Dei Hospital, Malta [63,64]. Ethical approval for the Swedish SIC-IBD cohort was obtained from the Uppsala Regional Ethics Committee (2010/313) and suspected IBD patients and controls were recruited from gastroenterological units at six Swedish hospitals.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All KINDRED cohort data are stored and managed by the PopGen biobank at the Institute of Epidemiology at Kiel University, Germany. Researchers can apply for data access to the KINDRED data by submitting a research proposal, including the scientific background, research question, success prospects, study design, potential conclusions, and scientific collaborators of their study, at the local biobank P2N via the following form: http://www.uksh.de/p2n/Information+for+Researchers.html. Due to the informed consent obtained from the participants, phenotypes, as well as genotyping and all 16S rRNA gene-sequencing data, can not be deposited publicly.
Raw sequence data and relevant meta-data can be accessed online under the accession number PRJEB44440 (Malta IBD cases in remission), PRJEB47161 (Malta treatment naive IBD cases), PRJEB47162 (Malta controls) [63,64]; and data of the Swedish SIC-IBD inception cohort will be made available under the accession number PRJEB77933 at the European Nucleotide Archive (https://www.ebi.ac.uk/ena/) after acceptance of this manuscript at a peer-reviewed journal.
Abbreviations used:
- CD
- Crohn’s disease
- IBD
- inflammatory bowel disease
- IC
- informed consent
- UC
- ulcerative colitis
- uIBD
- undetermined inflammatory bowel disease
- MD
- index-Microbiome dysbiosis index
- GMHI
- General Microbiome Health Index
- PRS
- Polygenic Risk Scores
